Impact Factor 3.519

Frontiers journals are at the top of citation and impact metrics

This article is part of the Research Topic

Molecular network study of pituitary adenomas

Review ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Endocrinol. | doi: 10.3389/fendo.2018.00768

The mechanism and pathways of dopamine and dopamine agonists in prolactinomas

 liu xiaoshuang1, Tang Chao2, Wen guodao3, Zhong Chunyu4, Yang Jin4, Zhu Junhao4 and  Chi Yuan Ma2*
  • 1Nanjing University, China
  • 2Nanjing General Hospital of Nanjing Military Command, China
  • 3Dongguan Tung Wah Hospital, China
  • 4Nanjing Medical University, China

Dopamine agonists (DAs) such as bromocriptine (BRC) and cabergoline(CAB) are the primary treatment choice for prolactinoma by inhibiting prolactin secretion and reducing tumour size. However, the mechanism of dopamine and DAs lead to the death of tumor cells are incompletely understood and some are even conflicting conclusions. The aim of this review is to summarize the different signaling pathways of dopamine and DAs in the treatment of prolactinomas to help better understanding of their functional and drug resistance mechanisms.

Keywords: Dopamine Agonists, Bromocriptine, cabergoline, programmed cell death, Apoptosis

Received: 31 Aug 2018; Accepted: 06 Dec 2018.

Edited by:

CARMEN E. GEORGESCU, Iuliu Hațieganu University of Medicine and Pharmacy, Romania

Reviewed by:

Hiroshi Nishioka, Department of Hypothalamic and Pituitary surgery, Toranomon Hospital, Japan
Sergio P. Toledo, Federal University of São Paulo, Brazil  

Copyright: © 2018 xiaoshuang, Chao, guodao, Chunyu, Jin, Junhao and Ma. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: MD, PhD. Chi Yuan Ma, Nanjing General Hospital of Nanjing Military Command, Nanjing, China, machiyuan_nju@126.com